Track topics on Twitter Track topics that are important to you
The CEO of French firm Advicenne explains why the company did not win an accelerated EU assessment for its kidney...
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard...
Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC – FR0013296746), specializing in the development of adult and pediatric therapeutic products for the tr...
Authorization extends patient recruitment base of European Phase II/III CORAL study, previously authorized in France Regulatory News: Advicenne (Paris:ADVIC) (...
SummaryAdvicenne SA Advicenne is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic...
Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC - FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric the...
Advicenne (Euronext: ADVIC) is a pharmaceutical company developing pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Companyâs ...
We have published hundreds of Advicenne news stories on BioPortfolio along with dozens of Advicenne Clinical Trials and PubMed Articles about Advicenne for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advicenne Companies in our database. You can also find out about relevant Advicenne Drugs and Medications on this site too.